Hematopoietic stem/progenitor cells (HSPCs) reside in the bone marrow (BM) microenvironment and are retained there by the interaction of membrane lipid raft-associated receptors, such as the α-chemokine receptor CXCR4 and the α4β1-integrin (VLA-4, very late antigen 4 receptor) receptor, with their respective specific ligands, stromal-derived factor 1 and vascular cell adhesion molecule 1, expressed in BM stem cell niches. The integrity of the lipid rafts containing these receptors is maintained by the glycolipid glycosylphosphatidylinositol anchor (GPI-A). It has been reported that a cleavage fragment of the fifth component of the activated complement cascade, C5a, has an important role in mobilizing HSPCs into the peripheral blood (PB) by (i) inducing degranulation of BM-residing granulocytes and (ii) promoting their egress from the BM into the PB so that they permeabilize the endothelial barrier for subsequent egress of HSPCs. We report here that hematopoietic cell-specific phospholipase C-β2 (PLC-β2) has a crucial role in pharmacological mobilization of HSPCs. On the one hand, when released during degranulation of granulocytes, it digests GPI-A, thereby disrupting membrane lipid rafts and impairing retention of HSPCs in BM niches. On the other hand, it is an intracellular enzyme required for degranulation of granulocytes and their egress from BM. In support of this dual role, we demonstrate that PLC-β2-knockout mice are poor mobilizers and provide, for the first time, evidence for the involvement of this lipolytic enzyme in the mobilization of HSPCs.

Document Type


Publication Date


Notes/Citation Information

Published in Leukemia, v. 30, issue 4, p. 919-928.

© 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Digital Object Identifier (DOI)


Funding Information

This work was supported by NIH Grants 2R01 DK074720 and R01HL112788, the Stella and Henry Endowment and Maestro Grant 2011/0/A/NZ4/00035 (to MZR) and the UK COBRE Early Career Program (P20 GM103527), and NIH Grant R56 HL124266 to ABL.

Related Content

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu).

leu2015315x1.ppt (461 kB)
Supplementary Figure 1.

leu2015315x2.ppt (206 kB)
Supplementary Figure 2.

leu2015315x3.ppt (308 kB)
Supplementary Figure 3.

leu2015315x4.ppt (205 kB)
Supplementary Figure 4.

leu2015315x5.docx (25 kB)
Legends to Supplementary Figures.